Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome

Amulya A Nageswara Rao, Grace M. Arteaga, Ann M. Reed, James M. Gloor, Vilmarie Rodriguez

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Catastrophic antiphospholipid syndrome (CAPS) is a life-threatening condition characterized by small-vessel thrombi and a rapid onset of multiorgan system failure associated with systemic inflammatory response syndrome. Current treatment options include anticoagulants, corticosteroids, plasma exchange, and intravenous immunoglobulin, but these are not always effective. Rituximab, a chimeric anti-CD20 monoclonal antibody, may help eliminate autoreactive B cells and thus limit the rapid inflammatory process involved in CAPS. We describe the use of rituximab in the successful initial management of a probable case of pediatric CAPS.

Original languageEnglish (US)
Pages (from-to)536-538
Number of pages3
JournalPediatric Blood and Cancer
Volume52
Issue number4
DOIs
StatePublished - Apr 2009

Fingerprint

Antiphospholipid Syndrome
Pediatrics
Systemic Inflammatory Response Syndrome
Plasma Exchange
Intravenous Immunoglobulins
Anticoagulants
Adrenal Cortex Hormones
Thrombosis
B-Lymphocytes
Monoclonal Antibodies
Rituximab
Therapeutics

Keywords

  • Catastrophic antiphospholipid syndrome
  • Lupus anticoagulant;rituximab; thrombosis

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Medicine(all)

Cite this

Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome. / Rao, Amulya A Nageswara; Arteaga, Grace M.; Reed, Ann M.; Gloor, James M.; Rodriguez, Vilmarie.

In: Pediatric Blood and Cancer, Vol. 52, No. 4, 04.2009, p. 536-538.

Research output: Contribution to journalArticle

Rao, Amulya A Nageswara ; Arteaga, Grace M. ; Reed, Ann M. ; Gloor, James M. ; Rodriguez, Vilmarie. / Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome. In: Pediatric Blood and Cancer. 2009 ; Vol. 52, No. 4. pp. 536-538.
@article{f6f12c09cf7f486f9fbd4a2ab09f7af9,
title = "Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome",
abstract = "Catastrophic antiphospholipid syndrome (CAPS) is a life-threatening condition characterized by small-vessel thrombi and a rapid onset of multiorgan system failure associated with systemic inflammatory response syndrome. Current treatment options include anticoagulants, corticosteroids, plasma exchange, and intravenous immunoglobulin, but these are not always effective. Rituximab, a chimeric anti-CD20 monoclonal antibody, may help eliminate autoreactive B cells and thus limit the rapid inflammatory process involved in CAPS. We describe the use of rituximab in the successful initial management of a probable case of pediatric CAPS.",
keywords = "Catastrophic antiphospholipid syndrome, Lupus anticoagulant;rituximab; thrombosis",
author = "Rao, {Amulya A Nageswara} and Arteaga, {Grace M.} and Reed, {Ann M.} and Gloor, {James M.} and Vilmarie Rodriguez",
year = "2009",
month = "4",
doi = "10.1002/pbc.21878",
language = "English (US)",
volume = "52",
pages = "536--538",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome

AU - Rao, Amulya A Nageswara

AU - Arteaga, Grace M.

AU - Reed, Ann M.

AU - Gloor, James M.

AU - Rodriguez, Vilmarie

PY - 2009/4

Y1 - 2009/4

N2 - Catastrophic antiphospholipid syndrome (CAPS) is a life-threatening condition characterized by small-vessel thrombi and a rapid onset of multiorgan system failure associated with systemic inflammatory response syndrome. Current treatment options include anticoagulants, corticosteroids, plasma exchange, and intravenous immunoglobulin, but these are not always effective. Rituximab, a chimeric anti-CD20 monoclonal antibody, may help eliminate autoreactive B cells and thus limit the rapid inflammatory process involved in CAPS. We describe the use of rituximab in the successful initial management of a probable case of pediatric CAPS.

AB - Catastrophic antiphospholipid syndrome (CAPS) is a life-threatening condition characterized by small-vessel thrombi and a rapid onset of multiorgan system failure associated with systemic inflammatory response syndrome. Current treatment options include anticoagulants, corticosteroids, plasma exchange, and intravenous immunoglobulin, but these are not always effective. Rituximab, a chimeric anti-CD20 monoclonal antibody, may help eliminate autoreactive B cells and thus limit the rapid inflammatory process involved in CAPS. We describe the use of rituximab in the successful initial management of a probable case of pediatric CAPS.

KW - Catastrophic antiphospholipid syndrome

KW - Lupus anticoagulant;rituximab; thrombosis

UR - http://www.scopus.com/inward/record.url?scp=62449319386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62449319386&partnerID=8YFLogxK

U2 - 10.1002/pbc.21878

DO - 10.1002/pbc.21878

M3 - Article

VL - 52

SP - 536

EP - 538

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -